Stock Research for ATNM

ATNM

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ATNM Stock Chart & Research Data

The ATNM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATNM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ATNM Due diligence Resources & Stock Charts

The ATNM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ATNM Detailed Price Forecast - CNN Money CNN View ATNM Detailed Summary - Google Finance
Yahoo View ATNM Detailed Summary - Yahoo! Finance Zacks View ATNM Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ATNM Trends & Analysis - Trade-Ideas Barrons View ATNM Major Holders - Barrons
NASDAQ View ATNM Call Transcripts - NASDAQ Seeking View ATNM Breaking News & Analysis - Seeking Alpha
Spotlight View ATNM Annual Report - CompanySpotlight.com OTC Report View ATNM OTC Short Report - OTCShortReport.com
TradeKing View ATNM Fundamentals - TradeKing Charts View ATNM SEC Filings - Bar Chart
WSJ View Historical Prices for ATNM - The WSJ Morningstar View Performance/Total Return for ATNM - Morningstar
MarketWatch View the Analyst Estimates for ATNM - MarketWatch CNBC View the Earnings History for ATNM - CNBC
StockMarketWatch View the ATNM Earnings - StockMarketWatch MacroAxis View ATNM Buy or Sell Recommendations - MacroAxis
Bullish View the ATNM Bullish Patterns - American Bulls Short Pains View ATNM Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ATNM Stock Mentions - StockTwits PennyStocks View ATNM Stock Mentions - PennyStockTweets
Twitter View ATNM Stock Mentions - Twitter Invest Hub View ATNM Investment Forum News - Investor Hub
Yahoo View ATNM Stock Mentions - Yahoo! Message Board Seeking Alpha View ATNM Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ATNM - SECform4.com Insider Cow View Insider Transactions for ATNM - Insider Cow
CNBC View ATNM Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ATNM - OTC Markets
Yahoo View Insider Transactions for ATNM - Yahoo! Finance NASDAQ View Institutional Holdings for ATNM - NASDAQ


Stock Charts

FinViz View ATNM Stock Insight & Charts - FinViz.com StockCharts View ATNM Investment Charts - StockCharts.com
BarChart View ATNM Stock Overview & Charts - BarChart Trading View View ATNM User Generated Charts - Trading View




Latest Financial News for ATNM


Actinium Forms Nuclear Medicine Focused Advisory Board to Facilitate Pipeline Clinical Development and Iomab-B Commercial Planning
Posted on Tuesday July 17, 2018

NEW YORK, July 17, 2018-- Actinium Pharmaceuticals, Inc., today announced that it has appointed the members of its Nuclear Medicine Clinical Advisory Board. The following nuclear medicine physicians and ...


Actinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients
Posted on Monday July 09, 2018

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), provided a reminder that it will host a webcast on July 10, 2018 at 8:00 AM ET. The webcast will discuss the Company’s previously announced Actimab-A MRD clinical trial for patients with AML who are in remission but have detectable minimal residual disease (MRD).


Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks
Posted on Monday July 02, 2018

On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.


Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
Posted on Thursday June 28, 2018

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), today announced that Dr. Joseph Jurcic, Director of the Hematologic Malignancies Section and Professor of Medicine at Columbia University Medical Center, has initiated Actimab-A MRD, a new clinical trial for patients with AML who are in remission but have detectable minimal residual disease (MRD).  The trial will study the safety/tolerability of Actimab-A in the postremission consolidation setting and include dose finding analyses.  The trial will also study the impact of Actimab-A on minimal residual disease (MRD) as well as progression-free (PFS) and overall survival (OS) rates. The investigational new drug (IND) application for this trial has been cleared by the FDA.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.